Belite Bio targets completing stargardt NDA rolling submission in Q2 2026 while planning a 30-40 member U.S. launch team (NASDAQ:BLTE)

Belite Bio (BLTE) Q1 2026 earnings call: FDA rolling NDA for Stargardt, DRAGON updates, launch plans, burn and $799M cash—read key takeaways.

Read on WOBR AI →